Deficiency of adenosine deaaminaae (ADA): Clinical, biochemical, molecular and treatment aspects;Deficiencia de adenosina desaminasa (ADA): Aspectos clínicos, bioquímicos, moleculares y de tratamiento

Revista de Investigacion Clinica

Volumn 63, Issue 1, 2011, Pages 75-83

  Tintos Hemández, Jesús Alonso ^a,b   Dávalos Rodriguez, Ingrid Patricia ^a,b  

^a INSTITUTO MEXICANO DEL SEGURO SOCIAL   (Mexico)

^b UNIVERSITY OF GUADALAJARA   (Mexico)

Author keywords

Adenosine desaminase deficiency; Purine metabolism; Severe combined immunodeficiency disease (SCID)

Indexed keywords

ADENOSINE DEAMINASE; TOXIN;

ADENOSINE DEAMINASE DEFICIENCY; ARTICLE; B LYMPHOCYTE; HEARING IMPAIRMENT; HUMAN; IMMUNE DEFICIENCY; IMMUNE RESPONSE; KIDNEY DISEASE; LIVER DISEASE; LYMPHOCYTE FUNCTION; NEUROLOGIC DISEASE; RECURRENT INFECTION; SEIZURE; SKELETON MALFORMATION; T LYMPHOCYTE;

ADENOSINE DEAMINASE; DEFICIENCY DISEASES; HUMANS;

EID: 79955913504     PISSN: 00348376     EISSN: 00348376     Source Type: Journal    
DOI: None     Document Type: Article

References (60)

1. Notarangelo LD. Primary immunodeficiencies (PIDs) presenting with cytopenias. Hematol 2009;139-143.
2. Online Mendelian Inheritance in Man, OMIM (TM). Johns Hopkins University, Baltimore, MD. MIM Number: (102700): (2009): URL: http://www.ncbi.nlm.nih.gov/ omim
3. Mainardi V, Brugo MA, Tassi GC. Immunodeficiencies and enzyme deficiencies. 1st Sieroter Milan 1978;31; 57(2):178-91.
4. Arredondo-Vega FX, Santisteban I, Daniels S, Toutain S, Hershfield MS. Adenosine Deaminase Deficiency: Genotype-Phenotype Correlations Based on Expressed Activity of 29 Mutant Alleles. Am J Hum Genet 1998;63:1049-50.
5. Yee A, De Ravin SS, Eliot E, Ziegler JB. Severe combined immunodeficiency: a national surveillance study. Pediatr Allergy Immunol 2008;19(4):298-30.
6. Ozdemir Oner, M. D. Severe combined immune deficiency in an adenosine deaminase-deficient patient. Allergy Asthma Proc 2006;27:172-4.
7. Booth C, Gaspar HB. Pegademase bovine (PEG-ADA) for the treatment of infants and children with severe combined immunodeficiency (SCID). Biologies: Targets & Therapy 2009;3:349-58.
8. Hirschhorn R. Clinical delineation of adenosine deaminase deficiency. In: Elliot K, Whelan J (Eds.) Enzyme Defects and Immune Dysfunction Ciba Foundation Symposium 68. New York: Excerpta Medica; 1979, p. 35.
9. Buckley RH, Schiff RI, Market ML, Williams LW, Harville TO, Roberts JL, Puck, JM. Human severe combined immunodeficiency; genetic, phenotypic and functional diversity in one hundred eight infants. J Pediatr 1997;130:378-87. (Pubitemid 27492681)
10. Nofech-Mozes Y, Blaser SI, Kobayashi J, Grunebaum E, Roifman CM. Neurologic abnormalities in patients with adenosine deaminase deficiency. Pediatr Neurol 2007;37(3):218-21. (Pubitemid 47321056)
11. Titman P, Pink E, Skucek E, O'Hanlon K, Cole TJ, Gaspar J, Xu-Bayford, et al. Cognitive and behavioral abnormalities in children after hematopoietic stem cell transplantation for severe congenital immunodeficiencies. Blood 2008;112(9):3907-13.
12. Howard, Alba GM, Gallo G, Rimoin, DL, Kamino H, Hirschhorn R. Pathologic Findings in Adenosine-Deaminase-Deficient Severe Combined Immunodeficiency: I. Kidney, Adrenal and Chondro-osseous Tissue Alterations. Am J Pathol 1985;120:157-169. (Pubitemid 15037983)
13. Scriver, Berudet, Valle, Sly. The metabolic & molecular bases of inherited disease. 8th Ed. Mc Graw Hill; 2001, p. 2513-30, 2585-625.
14. William L, Nyhan, Bruce A, Barshop, Pinar T. Atlas of Metabolic diseases. 2nd Ed. Hodder Arnold; 2005, p. 452-7.
15. Howard R, Hirschhorn R, Alba GM. Pathologic findings in Adenosine Deaminase Deficient-Severe Combined Immunodeficiency; II. Thymus, spleen, lymph node and gastrointestinal tract lymphoid tissue alterations. Am J Pathol 1989;135:1145-56. (Pubitemid 20026534)
16. Vaca G, Sánchez-Corona J, Olivares N, Medica C, Ibarra B, Cantú JM. A simple rapid fluorescent assay for adenosine deaminase activity. Ann Génét 1979;22(3):182-4. (Pubitemid 10213297)
17. Lainka E, Hershfield MS, Santisteban I, Bali P, Seibt A, Neubert J, Friedrich W, Niehues T. Polyethylene Glycol-Conjugated Adenosine Deaminase (ADA) therapy provides temporary immune reconstitution to a child with delayed-onset ADA deficiency. Clin Diagn Lab Immunol 2005;12(7):861-6. (Pubitemid 40993287)
18. Hershfield M. Adenosine Deaminase Deficiency. Gene Reviews 2006;1-16.
19. Ariga T, Oda N, Sanstisteban I, Arredondo-Vega FX, Shioda M, Ueno H, Terada K, et al. Molecular basis for paradoxical carriers of Adenosine Deaminase (ADA) Deficiency that show extremely low levels of ADA activity in peripheral blood cells without immunodeficiency. J Immunol 2001;166:1698-1702. (Pubitemid 32114652)
20. Fischer A, Le Deist F, Hacein-Bey-Abina S, Andre-Schmutz I, Basile Gde S, De Villartay JP, Cavazzana-Calvo M. Severe combined immunodeficiency. A model disease for molecular immunology and therapy. Immunol Rev 2005;203:98-109. (Pubitemid 40179696)
21. Abdullah Alangari, Abdullah Al-Harbi, Abdulaziz Al-Ghonaium, Santisteban I, Hershfield M. Purine nucleoside phosphorylase deficiency in two unrelated Saudi patients. Ann Saudi Med 2009;29(4):309-12.
22. Schrader WP, Pollara B, Meuwissen HJ. Characterization of the residual adenosine deaminating activity in the spleen of a patient with combined immunodeficiency disease and adenosine deaminase deficiency. Proc Natl Acad Sci U. S. A 1978;75(1):446-50. (Pubitemid 8287544)
23. Hirschhorn R, Yang DR, Israni A. An Asp8Asn substitution results in the adenosine deaminase (ADA) genetic polymorphism (ADA 2 allozyme): occurrence on different chromosomal backgrounds and apparent intragenic Crossover. Ann Hum Genet 1994;58(P1): 1-9. (Pubitemid 24110508)
24. Pacheco R, Martinez-Navio JM, Lejeune M, Climent N, Oliva H, Gatell JM, Gallart T, et al. CD26, adenosine deaminase and adenosinereceptors mediate costimulatory signals in the immunological synapse. PNAS 2005;102(2):9583-8. (Pubitemid 40981724)
25. Gakis C. Adenosine deaminase (ADA) isoenzymes ADA1 and ADA2: diagnostic and biological role. Eur Respir J 1996;9:632-3. (Pubitemid 26167862)
26. Zavialov AV, Gracia IE, Glaichenhaus N, Franco R, Zavialov AV, Lauvau G. Human adenosine deaminase 2 induces differentiation of monocytes into macrophages and stimulates proliferation of T helper cells and macrophages. J Leukoc Biol 2010;88:1-12.
27. Moore KL, Persaud TVN. Embriologia clinica. 8a Ed. en espanol. The developing human. Clinically Oriented Embriology. Elsevier; 2008, p. 212-41.
28. Kutlar I, Aksoy F, Koyluoglu O, Ugur MG, Balat O, Tarakcioglu M. Adenosine deaminase activity in serum and placenta of patients with anembryonic pregnancies and missed abortions. Arch Gynecol Obstet 2005;272(2):124-6. (Pubitemid 40941746)
29. Meng JP, Zhang FP, Huhtaniemi I, Pakarinen P. Characterization and developmental expression of a testis-specific Adenosine Deaminase mRNA in the mouse. J Androl 1997;18(1):88-95. (Pubitemid 27114467)
30. Doleal T. Adenosine deaminase. Review of physiological roles 2001. URL: http://www.entu.cas.cz/fyziol/seminars/ada.html
31. Online Mendelian Inheritance in Man, OMIM (TM). Johns Hopkins University, Baltimore, MD. MIM Number: {102730}: {2010}: URL: http://www.ncbi.nlm.nih.gov/ omim
32. Sanchez-Corona J, Garcia-Cruz D, Mendoza C, Cantú JM, Ramos-Zepeda M, Rivas E. Increase adenosine deaminase activity in a patient with cartilage-hair hipoplasia. Ann Géné 1990;33(2):99-102. (Pubitemid 20268850)
33. Wiginton DA, Kaplan DJ, States JC, Akeson AL, Perme CM, Bilyk IJ, Vaughn AJ, et al. Complete sequence of the gene for human adenosine deaminase. Biochemistry 1986;16:25 (25):8234-44. (Pubitemid 17233520)
34. Dusing MR, Wiginton DA. Spl is essential for both enhancer-mediated and basal activation of the TATA-less human adenosine deaminase promoter. Nucleic Acids Res 1994;22:669-77. (Pubitemid 24158779)
35. Tullo A, Mastropasqua G, Bourdon JC, Centonze P, Gostissa M, Costanzo A, Levrero M, et al. Adenosine deaminase, a key enzyme in DNA precursors control, is a new p73 target. Oncogene 2003;22:8738-48. (Pubitemid 38010498)
36. Frederiksen. Specificity of adenosine deaminase toward adenosine and 2'-deoxyadenosine. Arch 28. Biochem Biophys 1966;113:383-8.
37. Wyngaarden JB, Kelly WN. Gout and Hyperuricemía. New York: Grune & Stratton; 1976, p. 512.
38. Fernández-Mejía C. Inmunodeficiencia combinada severa por déficit de la enzima Adenosin-desaminasa. Inmunologia 1988;7 (2).
39. Michael S. Hershfield, Kredic NM. In vivo' inactivation of erythrocyte S-Adenosylhomocysteine Hydrolase by 2'-Deoxyadenosine in Adenosine Deaminase-Deficient Patients. J Clin Invest 1979;63:807-11. (Pubitemid 9167052)
40. Aldrich MB, Chen W, Blackburn MR, Martinez-Valdez H, Datta SK, Kellems RK. Impaired germinal center maturation in Adenosine Deaminase Deficiency. J Immunol 2003;171:5562-70. (Pubitemid 37432847)
41. Young K, Tong Z, Lee KW. Poly ADP-ribosylation by PARP-1: 'PAR-laying' NAD + into a nuclear signal. Genes Dev 2005;19:1951-67.
42. Megan S, Lim and Kojo SJ. Elenitoba-Johnson. The Molecular Pathology of Primary Immunodeficiencies. J Molecular Diagnostics 2004;6(2):59-83. (Pubitemid 38584544)
43. Hershfield MS. Apparent suicide inactivation of human lymphoblast S Adenosylhomocysteine Hydrolase by 2'-Deoxyadenosine and Adenine Arabinoside. J Biolog Chemistry 1979;254:22-5. (Pubitemid 9137439)
44. Benveniste P, Zhu W, Cohen A. Interference with thymocyte differentiation by an inhibitor of S-adenosylhomocysteine hydrolase. J Immunol 1995;155:536-44.
45. Sauer AV, Mrak E, Jofra HR, Zacchi E, Cavani F, Casiraghi M, Grunebaum E, et al. ADA-deficient SCID is associated with a specific microenvironment and bone phenotype characterized by RANKL/OPG imbalance and osteoblast insufficiency. Blood First Edition Paper, prcpublished online. 2009; DOI 10.1182/blood-2009-03-209221.
46. Cancrini C, Ferrua F, Scarselli A, Brigida I, Romìti ML, Barera G, Finocchi A, et al. Role of reduced intensity conditioning in T-cells and B-cell immune reconstitution after HLA-identical bone marrow transplantation in ADA-SCID. Haematologica 2010;96:1-17.
47. Dvorak and MJ Cowan. Hematopoietic stem cell transplantation for primary immunodeficiency Disease. Bone Marrow Transplantation 2008;41:119-26. (Pubitemid 351188908)
48. Gaspar HB, Aiuti A, Porta F, Candotti F, Hershfield MS, Notarangelo LD. How I treat ADA deficiency. Blood 2009;114:3524-32.
49. Booth C, Hershfield M, Notarangelo L, et al. Management options for adenosine deaminase deficiency. Clin Immunol 2007;123(2):139-47.
50. Höníg M, Albert MH, Schulz A, Sparber-Sauer M, Schütz C, Belohradsky B, Güngör T, et al. Patients with adenosine deaminase deficiency surviving after hematopoietic stem cell transplantation are at high risk of CNS complications. Blood 2007;109(8):3595-602. (Pubitemid 46572555)
51. Polmar SH, Wetzler EM, Stern RC, Hirschhorn R. Restoration of in-vitro lymphocyte responses with exogenous adenosine deaminase in a patient with severe combined immunodeficiency. Lancet 1975;18; 2(7938):743-6.
52. Bax BE, Bain MD, Fairbanks LD, et al. A 9-yr evaluation of carrier erythrocyte encapsulated adenosine deaminase (ADA) therapy in a patient with adult-type ADA deficiency. Eur J Haematol 2007;79(4):338-48. (Pubitemid 47390137)
53. Veronese FM, Mero A. The impact of PEGylation on biological therapies. BioDrugs 2008;22(5):315-29.
54. Hershfield MS. PEG-ADA replacement therapy for adenosine deaminase deficiency: an update after 8.5 years. Clin Immunol Immunopathol 1995;76(3):P2: S228-S232.
55. Ozdemir O, Niehues. Increasing importance of stem cell gene therapy in adenosine deaminase deficiency? Clin Vaccine Immunol 2006;13(3):433-4.
56. Kaufman DA, Hershfield MS, Bocchini JA, Moissidis IJ, Jeroudi M, Bahna SL. Cerebral Lymphoma in an Adenosine Deaminase-Deficient Patient with Severe Combined Immunodeficiency Receiving Polyethylene Glycol-Conjugated Adenosine Deaminase. Pediatrics 2005;116: e876-e879. (Pubitemid 46056469)
57. Silver JN, Flotte TR. Towards a rAAV-based gene therapy for ADA-SCID: from ADA deficiency to current and future treatment strategies. Pharmacogenomics 2008;9(7):947-68.
58. Aiuti A, Cattaneo F, Galimberti S, Benninghoff U, Cassani B, Callegaro L, Scaramuzza S, et al. Gene therapy for immunodeficiency due to adenosine deaminase deficiency. N Engl J Med 2009;29; 360(5):518-21.
59. Qasim W, Gaspar HB, Thrasher AJ. Progress and prospects: gene therapy for inherited immunodeficiencies. Gene Therapy 2009;16:1285-129.
60. Zhang WX, Zhao W. Adenosine deaminase deficiency associated severe combined immunodeficiency with disseminated varicella infection after vaccination: a case report. Zhonghua Er Ke Za Zhi 2008;46(8):597-600.